Our immunology team has developed an advanced immunoassay and inflammation platform that provides cutting-edge preclinical in vitro and in vivo/ex vivo models. Our scientists utilise comprehensive immunophenotyping, as well as biomarkers with pharmacodynamic, predictive and surveillance utility to accelerate the discovery, characterisation and optimisation of treatments and drug targets. This comprehensive approach enhances your immunology research and development initiatives across a broad range of therapeutic areas, including oncology, inflammation, cardiology and neurology.
The immune system involves a complex interplay of distinct cell types, cell subsets and genetic and environmental factors. To support your research, Nuvisan offers an extensive portfolio of single and complex co-culture systems for screening compounds, validating biomarkers, assessing immunogenicity, and determining mode-of-action (MOA). Key assays include:
We are constantly expanding our hiPSC-derived cell portfolio in the cardiology and neurology indication spaces.
learn more
Advance precision medicine with Nuvisan’s expertise in biomarker discovery, supporting the transition from drug discovery to clinical development.
learn more
Enhance drug development success with ex vivo tissue models, focusing on primary cell assays that provide translational value in drug discovery.
learn more
Contact Us
Search